



- (51) **International Patent Classification:**
A61K 38/36 (2006.01) *A61K 38/48* (2006.01)
- (21) **International Application Number:**
PCT/US2015/046173
- (22) **International Filing Date:**
20 August 2015 (20.08.2015)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/039,809 20 August 2014 (20.08.2014) US
- (71) **Applicant:** PORTOLA PHARMACEUTICALS, INC.
[US/US]; 270 E. Grand Avenue, Suite 22, South San Francisco, California 94080 (US).
- (72) **Inventors:** WANG, Juan; c/o Portola Pharmaceuticals, Inc., 270 E. Grand Avenue, Suite 22, South San Francisco, California 94080 (US). SACHA, Gregory A.; c/o Portola Pharmaceuticals, Inc., 270 E. Grand Avenue, Suite 22, South San Francisco, California 94080 (US). NGUYEN, Phuong M.; c/o Portola Pharmaceuticals, Inc., 270 E. Grand Avenue, Suite 22, South San Francisco, California 94080 (US).
- (74) **Agents:** NIE, Alex Y. et al.; Sheppard Mullin Richter & Hampton LLP, 379 Lytton Avenue, Palo Alto, California 94301-1479 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) **Title:** LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE

(57) **Abstract:** The present disclosure relates to solutions and methods of preparing lyophilized formulations of factor Xa (fXa) antidotes. A suitable aqueous formulation suitable for lyophilization can include a fXa antidote, a solubilizing agent, a stabilizer, and a crystalline component, wherein the formulation does not collapse during lyophilization.

